Humacyte, Inc.
Nasdaq · Healthcare · Biological Products, (No Diagnostic Substances) · Durham, NC
HUMA chart
What traders are saying about $HUMA
Latest postsHumacyte, Inc. news
- Humacyte, Inc. Estimates – NASDAQ:HUMA
TradingView ·
- Humacyte reports positive trial results for dialysis access device
Investing.com ·
- Humacyte at ASN Kidney Week: Phase 3 Trial Built for Women Shows ATEV Advantage Over Fistula, Getting Patients Off Catheters Months Sooner
Yahoo Finance ·
- Phase 3 trial shows ATEV improves hemodialysis access for women, reducing catheter time by 91 days.
Pluang ·
- Why Humacyte, Inc. (HUMA) Outpaced the Stock Market Today
Yahoo Finance ·
- Humacyte to present interim Phase 3 V012 trial results for ATEV in women on dialysis
Traders Union ·
- Humacyte, Inc. (HUMA) Stock Drops Despite Market Gains: Important Facts to Note
Yahoo Finance ·
- Humacyte Provides Commercial Update and Highlights Rapid Acceleration of Symvess Adoption by Hospitals
Yahoo Finance ·
- Humacyte, Inc. (HUMA) Sees a More Significant Dip Than Broader Market: Some Facts to Know
Yahoo Finance ·
- Humacyte Announces Phase 3 V012 Trial Results for ATEV in Women Requiring Hemodialysis Access Accepted for a Late-Breaking Session Presentation at ASN Kidney Week 2026
Yahoo Finance ·
- Humacyte (HUMA) Stock Fair Value Moves Lower After Analyst Target Cuts
Yahoo Finance ·
- Flutter upgraded, AppFolio downgraded: Wall Street's top analyst calls
Yahoo Finance ·
Humacyte, Inc. key financials
| USD | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Revenue | $2.0M | $0 | – | – |
| Net income | -$40.8M | -$148.7M | -$110.8M | -$12.0M |
| Diluted EPS | $-0.26 | $-1.26 | $-1.07 | $-0.12 |
| Total assets (year end) | $116.4M | $137.9M | $128.2M | $204.3M |
| Cash and equivalents (year end) | $50.5M | $44.9M | $80.4M | $149.8M |
Calendar-year figures as reported to the SEC in XBRL filings.
Recent SEC filings
About Humacyte, Inc.
- Ticker
- HUMA (Nasdaq)
- Industry
- Biological Products, (No Diagnostic Substances)
- Headquarters
- Durham, NC
- Incorporated in
- DE
- Fiscal year end
- December 31
- SEC CIK
- 1818382
- Former names
- Alpha Healthcare Acquisition Corp.
Frequently asked questions
What exchange is Humacyte, Inc. listed on?
Humacyte, Inc. trades on the Nasdaq under the ticker symbol HUMA.
What industry is Humacyte, Inc. in?
Humacyte, Inc. is classified by the SEC under "Biological Products, (No Diagnostic Substances)", part of the Healthcare sector on StockTweeting.
Where is Humacyte, Inc. headquartered?
Humacyte, Inc.'s business address on file with the SEC is in Durham, NC.
When does Humacyte, Inc.'s fiscal year end?
Humacyte, Inc.'s fiscal year ends on December 31.
How much revenue did Humacyte, Inc. report?
Humacyte, Inc. reported $2.0M in revenue for calendar year 2025, according to its SEC filings.